专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06306897B1 Calanolides for inhibiting BTK 失效
标题翻译：氯化胆碱抑制BTK
公开(公告)号：US06306897B1
公开(公告)日：2001-10-23
申请号：US09354550
申请日：1999-07-15
申请人： Fatih M. Uckun , Elise Sudbeck
发明人： Fatih M. Uckun , Elise Sudbeck
IPC分类号： A61K3135
CPC分类号： C07D493/04 , A61K31/352 , A61K31/37 , C07D493/14
摘要： The invention provides calanolide compounds used as Tec family/BTK inhibitors, methods for their identification and use, and pharmaceutical compositions comprising calanolide Tec family/BTK inhibitors.
摘要翻译：本发明提供用作Tec家族/ BTK抑制剂的calanolide化合物，其鉴定和使用方法，以及包含calanolide Tec家族/ BTK抑制剂的药物组合物。

2. 发明授权

US07186736B1 NNI for treatment of multi-drug resistant HIV 失效
标题翻译： NNI用于治疗多重耐药性HIV
公开(公告)号：US07186736B1
公开(公告)日：2007-03-06
申请号：US09272821
申请日：1999-03-20
申请人： Fatih M. Uckun
发明人： Fatih M. Uckun
IPC分类号： A61K31/44 , A61K31/17
CPC分类号： A61K31/17
摘要： The present invention is directed to compounds and methods suitable for the treatment of HIV infection.
摘要翻译：本发明涉及适合于治疗HIV感染的化合物和方法。

3. 发明授权

US07038049B2 Haloanilino quinazolines and therapeutic use thereof 失效
标题翻译：卤代苯胺喹唑啉及其治疗用途
公开(公告)号：US07038049B2
公开(公告)日：2006-05-02
申请号：US10852076
申请日：2004-05-24
申请人： Fatih M. Uckun , Xing-Ping Liu , Rama Krishna Narla
发明人： Fatih M. Uckun , Xing-Ping Liu , Rama Krishna Narla
IPC分类号： C07D239/94 , A61K31/517 , A61P35/00 , A61P35/02
CPC分类号： C07D239/94
摘要： The present disclosure includes compounds, for example a compound according to formula I or a pharmaceutically acceptable salt thereof. The compounds of the present disclosure are useful in methods of treating cancerous conditions.
摘要翻译：本公开内容包括化合物，例如根据式I的化合物或其药学上可接受的盐。本公开的化合物可用于治疗癌症的方法。

4. 发明授权

US06864286B2 Inhibitors of the EGF-receptor tyrosine kinase and methods for their use 失效
标题翻译： EGF受体酪氨酸激酶的抑制剂及其使用方法
公开(公告)号：US06864286B2
公开(公告)日：2005-03-08
申请号：US09947862
申请日：2001-09-05
申请人： Fatih M. Uckun , Yaguo Zheng , Sutapa Ghosh
发明人： Fatih M. Uckun , Yaguo Zheng , Sutapa Ghosh
IPC分类号： A61P35/04 , C07C255/23 , C07D295/135 , A61K31/277 , C07C255/07
CPC分类号： C07D295/135 , C07C255/23
摘要： Novel compounds and pharmaceutical compositions useful as EGFR tyrosine kinase inhibitors. Methods of the invention include administration of the EGFR TK inhibitors to treat diseases characterized by enhanced expression of EGF, including cancers, particularly breast cancer. Additionally, a homology model representing the structure of EGFR kinase domain is provided, which model is useful for the rationally design and screening of compounds predicted to bind favorably to EGFR and to inhibit EGFR TK.
摘要翻译：用作EGFR酪氨酸激酶抑制剂的新型化合物和药物组合物。本发明的方法包括施用EGFR TK抑制剂以治疗特征在于增强EGF表达的疾病，包括癌症，特别是乳腺癌。此外，提供了表达EGFR激酶结构域的同源性模型，该模型可用于合理设计和筛选预期与EGFR结合的化合物并抑制EGFR TK。

5. 发明授权

US06800649B1 Method for inhibiting c-jun expression using JAK-3 inhibitors 失效
标题翻译：使用JAK-3抑制剂抑制c-jun表达的方法
公开(公告)号：US06800649B1
公开(公告)日：2004-10-05
申请号：US09345815
申请日：1999-06-30
申请人： Fatih M. Uckun
发明人： Fatih M. Uckun
IPC分类号： A01N4340
CPC分类号： C07D239/94 , A61K31/00 , A61K31/517
摘要： The invention provides a method for inhibiting c-jun activation in mammalian or avian cells comprising contacting the cells with a substance that inhibits the activity of Janus family kinase 3 (JAK-3). The invention also provides a therapeutic method for preventing or treating a pathological condition in a mammal wherein c-jun activation is implicated and inhibition of its activation is desired comprising administering to a mammal in need of such therapy, an effective amount of a substance that inhibits the activity of JAK-3. Novel compounds that are JAK-3 inhibitors, as well as pharmaceutical compositions comprising the compounds are also provided.
摘要翻译：本发明提供了抑制哺乳动物或禽类细胞中c-jun活化的方法，包括使细胞与抑制Janus家族激酶3（JAK-3）活性的物质接触。本发明还提供了预防或治疗其中涉及c-jun活化的哺乳动物的病理状况的治疗方法，其需要抑制其活化，包括对需要这种治疗的哺乳动物施用有效量的抑制 JAK-3的活动。还提供了作为JAK-3抑制剂的新型化合物，以及包含该化合物的药物组合物。

6. 发明授权

US06734207B2 Cytotoxic compounds 失效
标题翻译：细胞毒性化合物
公开(公告)号：US06734207B2
公开(公告)日：2004-05-11
申请号：US10125746
申请日：2002-04-18
申请人： Fatih M. Uckun , Shyi-Tai M. Jan
发明人： Fatih M. Uckun , Shyi-Tai M. Jan
IPC分类号： A61K3138
CPC分类号： C07D213/30 , C07D233/64 , C07D277/24 , C07D307/42 , C07D333/16 , C07D333/22 , C07D333/28
摘要： Compounds are described that bind to tubulin causing tubulin depolymerization and inhibiting tubulin polymerization. The compounds of the invention are therapeutically effective to inhibit cellular proliferation, for example, as effective anti-cancer agents. The compounds can also induce cytotoxicity in cells such as leukemia cells. The chemical structure of the compounds includes a furan, thiophene, thiazole, oxazole, or imidazole group at one end of the molecule (head) and a hydrophobic, aliphatic chain at the other end of the molecule (tail).
摘要翻译：描述了结合微管导致微管蛋白解聚和抑制微管蛋白聚合的化合物。本发明的化合物对于抑制细胞增殖是治疗有效的，例如作为有效的抗癌剂。这些化合物还可以诱导细胞如白血病细胞的细胞毒性。化合物的化学结构包括分子一端的呋喃，噻吩，噻唑，恶唑或咪唑基（头）和分子另一端的疏水性脂族链（尾）。

7. 发明授权

US06537766B1 Ikaros isoforms and mutants 失效
标题翻译： Ikaros异构体和突变体
公开(公告)号：US06537766B1
公开(公告)日：2003-03-25
申请号：US09435327
申请日：1999-11-05
申请人： Fatih M. Uckun , Mya L. Crotty
发明人： Fatih M. Uckun , Mya L. Crotty
IPC分类号： G01N33574
CPC分类号： C07K14/4705 , A61K48/00 , Y10T436/25
摘要： Specific Ikaros mutations, as well as the correlation of the presence of the specific Ikaros mutations and other wild-type non-DNA binding Ikaros isoforms with lymphoid cell abnormality is provided in the in the invention. Methods for detecting and treating lymphoid cell abnormality, including hematoloic malignancy, are also provided.
摘要翻译：在本发明中提供了特异性Ikaros突变，以及特异性Ikaros突变和其他野生型非DNA结合伊卡罗斯同种型与淋巴细胞异常的存在的相关性。还提供了检测和治疗淋巴细胞异常的方法，包括血液恶性肿瘤。

8. 发明授权

US06465450B2 Vanadium (IV) complexes containing catecholate ligand and having spermicidal activity 失效
标题翻译：含有儿茶酚酸配体的钒（IV）络合物，具有杀精活性
公开(公告)号：US06465450B2
公开(公告)日：2002-10-15
申请号：US09957524
申请日：2001-09-19
申请人： Phalguni Ghosh , Fatih M. Uckun , Osmond D'Cruz
发明人： Phalguni Ghosh , Fatih M. Uckun , Osmond D'Cruz
IPC分类号： A61K314745
CPC分类号： A61K31/555
摘要： Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.
摘要翻译：含有取代或未取代的儿茶酚酸配体的钒（IV）配合物，以及这些化合物的杀精活性。优选的化合物是含有烷基取代的儿茶酚酸盐配体的二茂铁（IV）络合物。

9. 发明授权

US06391921B1 Treatment of inflammation with 2,4,6-trihydroxy-&agr;-para-methoxyphenylacetophenone, or its pharmaceutically acceptable derivatives 有权
公开(公告)号：US06391921B1
公开(公告)日：2002-05-21
申请号：US09884245
申请日：2001-06-19
申请人： Fatih M. Uckun , Ravi Malaviya
发明人： Fatih M. Uckun , Ravi Malaviya
IPC分类号： A61K3112
摘要： 2,4,6-trihydroxy-&agr;-p-methoxyphenylacetophenone (also identified herein as “D-58”), or its pharmaceutically acceptable derivatives such as salt and ester forms, is administered for inhibiting inflammatory reactions. The treatment can be remedial or prophylactic. Examples of the conditions that can be treated include acute inflammatory reactions and allergic inflammatory reactions, and specific examples include allergy, asthma, arthritis, psoriasis, skin sunburn, inflammatory pelvic disease, inflammatory bowel disease, urethritis, uvitis, senusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, gastritis, enteritis, dermatitis, gingivitis, appendicitis, pancreatitis, cholocystitis and cholangitis. The 2,4,6-trihydroxy-&agr;-p-methoxyphenylacetophenone can be administered by various routes as needed.

10. 发明授权

US06326373B1 JAK-3 inhibitors for treating allergic disorders 失效
公开(公告)号：US06326373B1
公开(公告)日：2001-12-04
申请号：US09688755
申请日：2000-10-16
申请人： Fatih M. Uckun , Ravi Malavia , Elise A. Sudbeck
发明人： Fatih M. Uckun , Ravi Malavia , Elise A. Sudbeck
IPC分类号： A61K31505
CPC分类号： A61K31/517
摘要： Inhibitors of JAK3 kinase for the treatment of allergy inhibit mast cell degranulation an dmediator release.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式